When it comes to pharmacology, the big story these days is the development of the “glucagon-like peptide-1 (GLP-1) mimics,” ...
News-Medical.Net on MSN
Incretin-based diabetes drugs show potential protective effects against dementia
A large McGill University study has found that two classes of medications commonly prescribed for Type 2 diabetes, both ...
A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving ...
Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic ...
HealthDay News — Initiation of incretin receptor agonists (IRAs) is associated with lower continuous positive airway pressure (CPAP) use, hospitalization, and mortality among adults with obesity, type ...
News-Medical.Net on MSN
Most patients regain lost weight within two years of stopping obesity drugs
By Hugo Francisco de Souza A major BMJ review finds that the benefits of popular weight loss medications fade fast after ...
At the 44th Annual JP Morgan Healthcare conference 2026, Eli Lilly highlighted lepodisiran and muvalaplin as the key drugs in ...
Detailed price information for Skye Bioscience Inc (SKYE-Q) from The Globe and Mail including charting and trades.
Across all income levels, bariatric surgery resulted in better diabetes control than GLP-1s or similar medications, a study ...
New research reveals these medications impact everything from heart health to restaurant menus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results